The Nottingham prognostic index in primary breast cancer

By M. Galea, Roger W. Blamey, C. Elston, Ian O. Ellis. Breast Cancer Research and Treatment, 2005

947 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/8541e6d3d478b4c8c572226eca9030be45ef3e6e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Pathology and Forensic Medicine

Citations in the corpus

Expression of luminal and basal cytokeratins in human breast carcinoma (2004, positive): “This is a well-characterized series of primary breast cancer with a mean age of 53 (range 18–70 years) treated in a uniform way and has been used to study a wide range of potential prognostic factors and markers in breast cancer including histological grade [8], histological tumour type [9], vascula”
bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer (2012, background): “Furthermore, to evaluate independent prognostic impact of genes relative to the well-established breast cancer prognostic indexes, Nottingham Prognostic Index- (NPI)- and Adjuvant! Online (AOL)-adjusted Cox proportional hazards models are systematically performed [19, 20].”
Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research (2013, background): “Nottingham Prognostic Index Survival in 387 women with primary, operable breast cancer [6,74] Many studies, including an external validation in 9149 Danish patients [75] Cited in guidelines.”
Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist (2014, background): “Prognostic models may involve models for individuals with a particular health condition, such as prediction of recurrence or death after diagnosis of breast cancer [8] or mortality after cardiac surgery [9], but also includes models for predicting the occurrence of future outcomes in apparently heal”
Prognostic markers in triple‐negative breast cancer (2007, background): “2 tumor size (cm) þ grade (1–3) þ lymph node score (1–3).(19) This index predicts the survival of patients with invasive breast cancer, and it can define 3 subsets of patients with different chances of dying from breast cancer; good ( 3.”
Prognosis and prognostic research: what, why, and how? (2009, methodology): “are widely used in primary care to determine the indication for cholesterol lowering and antihypertensive drugs. Examples from secondary care include use of the Nottingham prognostic index to estimate the long term risk of cancer recurrence or death in breast cancer patients,”
Minimum sample size for developing a multivariable prediction model: PART II ‐ binary and time‐to‐event outcomes (2018, methodology): “Applying Equation (9) within Equation (7), we can now express SVH in terms of R(2)CS_adj, rather than R 2 CS_app”